Education
About Us
Working with TipRanks
Follow Us
Bio-Rad Laboratories (BIO)
NYSE:BIO
BIO Stock Chart & Stats
$327.28
-$1.36(-0.40%)
At close: 4:00 PM EST
$327.28
-$1.36(-0.40%)
Day’s Range― - ―
52-Week Range$211.43 - $373.69
Previous CloseN/A
Volume33.84K
Average Volume (3M)234.66K
Market Cap
$8.84B
Enterprise Value$7.52B
Total Cash (Recent Filing)$1.42B
Total Debt (Recent Filing)$1.40B
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Feb 12, 2026EPS Estimate
2.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.26
Shares Outstanding21,906,399
10 Day Avg. Volume235,513
30 Day Avg. Volume234,655
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.41
Price to Sales (P/S)3.61
P/FCF Ratio34.82
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue2.94
Enterprise Value/Gross Profit5.63
Enterprise Value/Ebitda-12.11
Forecast
1Y Price Target
$369.25Price Target Upside12.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)9.96
Revenue Forecast (FY)$2.59B
Bulls Say, Bears Say
Bulls Say
Product PerformanceProcess chromatography grew mid-teens percentage in the quarter, and management was constructive on consumables overall.
Bears Say
Financial PerformanceForecasts for Bio-Rad's revenue and adjusted EBITDA have been reduced, reflecting a less optimistic outlook.
Growth ForecastBio-Rad Laboratories is expected to experience lower growth in their Life Sciences segment due to recent US policy changes and uncertainty around NIH funding.
Bio-Rad Laboratories News
BIO FAQ
What was Bio-Rad Laboratories’s price range in the past 12 months?
Bio-Rad Laboratories lowest stock price was $211.43 and its highest was $373.69 in the past 12 months.
What is Bio-Rad Laboratories’s market cap?
Bio-Rad Laboratories’s market cap is $8.84B.
When is Bio-Rad Laboratories’s upcoming earnings report date?
Bio-Rad Laboratories’s upcoming earnings report date is Feb 12, 2026 which is in 90 days.
How were Bio-Rad Laboratories’s earnings last quarter?
Bio-Rad Laboratories released its earnings results on Oct 29, 2025. The company reported $2.26 earnings per share for the quarter, beating the consensus estimate of $1.954 by $0.306.
Is Bio-Rad Laboratories overvalued?
According to Wall Street analysts Bio-Rad Laboratories’s price is currently Undervalued.
Does Bio-Rad Laboratories pay dividends?
Bio-Rad Laboratories does not currently pay dividends.
What is Bio-Rad Laboratories’s EPS estimate?
Bio-Rad Laboratories’s EPS estimate is 2.81.
How many shares outstanding does Bio-Rad Laboratories have?
Bio-Rad Laboratories has 21,906,399 shares outstanding.
What happened to Bio-Rad Laboratories’s price movement after its last earnings report?
Bio-Rad Laboratories reported an EPS of $2.26 in its last earnings report, beating expectations of $1.954. Following the earnings report the stock price went down -4.651%.
Which hedge fund is a major shareholder of Bio-Rad Laboratories?
Currently, no hedge funds are holding shares in BIO
Bio-Rad Laboratories Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$369.25 (12.82% Upside)
$369.25 (12.82% Upside)
Blogger Sentiment
Bullish
BIO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $214.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 26.2%
Last 30 Days ▲ 26.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.21%
12-Months-Change
Fundamentals
Return on Equity
-9.50%
Trailing 12-Months
Asset Growth
-8.55%
Trailing 12-Months
Company Description
Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. is a global leader in the life sciences and clinical diagnostics sectors, providing innovative products and solutions that enhance research and healthcare. Founded in 1952, the company operates in two primary segments: Life Science and Clinical Diagnostics. Bio-Rad's core offerings include a wide range of reagents, instruments, and software used in laboratories for applications such as drug discovery, genetic research, and clinical diagnostics, enabling scientists and healthcare professionals to achieve accurate results efficiently.
BIO Company Deck
BIO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Bio-Rad showed resilience in certain areas such as process chromatography and digital PCR strategy, but faced challenges in the Life Science segment and gross margin declines. The company maintained its full-year guidance despite these challenges, indicating cautious optimism.View all BIO earnings summariesBIO Net sales Breakdown
59.92% Clinical Diagnostics
40.06% Life Science
0.02% Other
BIO Stock 12 Month Forecast
Average Price Target
$369.25
▲(12.82% Upside)
Technical Analysis
Ownership Overview
22.35% Insiders
31.32% Mutual Funds
0.13% Other Institutional Investors
29.58% Public Companies and
Individual Investors